BiTE-ing into prostate cancer with bispecific T cell engagers
BiTE-ing into prostate cancer with bispecific T cell engagers Abstract Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T cell engager, AMG 160, which binds PSMA and CD3 to induce T cell-driven cytolytic activity against prostate […]
Read More